Showing results (431-440 of 587) with videos related to
Sort By:
Pageof 59
Current Oncology (Toronto, Ont.)|April 21, 2022
Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC StudyFiona Turkes, Annette Bryant, Ruwaida Begum, et al.Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.The Lancet. Oncology|April 13, 2013
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trialRoger D James, Robert Glynne-Jones, Helen M Meadows, et al.Cancers|May 27, 2026
Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre ExperienceKai Tai Derek Yeung, Simon Gomberg, William Hodgson, et al.The Lancet. Haematology|April 30, 2025
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trialMichael Northend, William Wilson, Kushani Ediriwickrema, et al.The Lancet. Oncology|March 8, 2014
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trialKirit M Ardeshna, Wendi Qian, Paul Smith, et al.Eclinicalmedicine|September 4, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 studyMarek Trněný, Abraham Avigdor, Matthew S McKinney, et al.The British Journal of Surgery|February 18, 2022
Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinomaArnaldo N S Silva, Yuichi Saito, Takaki Yoshikawa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal CancerFilippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.The Lancet. Oncology|December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo E R Ford, Andrea Marshall, John A Bridgewater, et al.Pageof 59